Bayes 2022

DAY 1 – 12th October

TIME
SPEAKER
AFFILIATION
8:30 - 9:00
Registration
8:30 - 12:30
John Scott, Scott Berry, Telba Irony
FDA, Berry Consultants, Janssen
Bayesian Innovative Clinical Trial Design in Practice
12:30 - 13:30
Lunch
13:30 - 13:45
Welcome and Opening
13:45 - 14:15
Heng Li
FDA
Utilizing real-world data to expedite a traditional clinical study: A Bayesian strategy
14:15 - 14:35
Binbing Yu (Fabio Rigat)
JNJ
A conservative approach to leveraging external evidence for effective clinical trial design
14:35 - 14:55
Zitong Wang
Johns Hopkins
Learning and Predicting from Dynamic Models for COVID-19 Patient Monitoring
14:55 -15:20
Coffee Break
15:20 - 15:50
Fan Li
Duke University
Propensity Score Overlap Power Prior for Integrating Real World Data in Clinical Trials
15:50 - 16:10
Nathan T. James
Berry Consultants
Bayesian Population Pharmacokinetic Analysis in Children using Real World Data from Electronic Health Records and Remnant Specimens
16:10 - 16:30
Ben Thompson
Confirm Solutions
Outlaw: Nano-second INLA-based Bayesian inference for proof-by-simulation
16:30 - 16:50
Krishna Padmanabhan
Cytel
MCMC vs. INLA in Bayesian Adaptive Clinical Trial designs: Comparing Simulation based and Approximate Bayesian Inference
16:50 - 17:20
Lei Nie
FDA
Bayesian dynamic borrowing methods in clinical trials
17:20 - 17:40
Eric Novik
Generable
Communicating models and uncertainty, a multi-industry perspective

The BAYES Organising Committee is delighted to invite all registered attendees to a social dinner at the Bethesdan Hotel tonight at 6:30 pm.

DAY 2 – 13th October

TIME
SPEAKER
AFFILIATION
8:30 - 9:00
John Scott
FDA
An overview of estimands and how Bayes can help
09:00 - 09:20
Anna Heath
The Hospital for Sick Children (IMPaCT Lab)
Selecting the superior treatment in Bayesian two-stage adaptive trials without the common control arm using the SUCRA and the probability of the first rank.
09:20 - 09:40
Yangfan Ren
Bayer and Rice U.
Bayesian interim prediction of recurrent events in clinical trials
09:40 - 10:00
Ruitao Lin
MD Anderson
BOIN-Comb: A easy-to-implement and well-performing Bayesian optimal interval design for dose finding in drug-combination trials
10:00 - 10:20
Coffee Break
10:20 - 10:50
Silvia Calderazzo
German Cancer Research Center (DKFZ)
Coping with Information Loss and the Use of Auxiliary Sources of Data for Unplanned Clinical Trial Disruptions
10:50 - 11:10
Tengjie Tang
Duke University
Comparing frequentist and Bayesian statistical methods to assess effect moderation by combining multiple studies with individual participant-level data
11:10 - 11:30
Danni Wu
NYU Langone
Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring
11:30 - 12:00
Satrajit Roychoudhury
Pfizer Inc.
Robust Bayesian Approaches for Basket Trial Design with Rare Cancer Indications
12:00 - 12:20
Alex Kaizer
University of Colorado Anschutz Medical Campus
A Sequential Basket Trial Design Based on Multi-Source Exchangeability with Predictive Probability Monitoring
12:20 - 13:30
Lunch
13:30 - 14:00
James Travis
FDA
Hierarchical Models in the Analysis of Master protocols for Rare Diseases
14:00 - 14:20
Will Landau
Lilly
Bayesian methods for placebo borrowing in master protocols
14:20 - 14:50
Meg Gamalo
Pfizer
Calibrating Data-based Priors Through Bounded Functions
14:50 - 15:10
Matt Psioda
GSK
Prior Elicitation and Pediatric/Adolescent Trial Design Evaluation in Cases with Anticipated Efficacy Attenuation Compared to Adults
15:10 - 15:40
Coffee Break
15:40 - 16:10
Mark Rothmann
FDA
Drug development and decision-making in pediatric settings leveraging adult results
16:10 - 16:30
Saurabh Mukhopadhyay
Abbvie
Assessing synergy, extend, and impact of leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing
16:30 - 16:50
Mingyuan Li
JHU
Bayesian penalized monotone regression for quantifying Alzheimer disease progression with biomarkers
16:50 - 17:10
Adarsh Joshi
Takeda
Bayesian algorithms for analyzing large biomarker panels in support of early phase immuno-oncology drug development
17:10 - 17:30
Hongtao Zhang
Merck
Improving the Performance of Bayesian Logistic Regression Model with Overdose Control

DAY 3 – 14th October

TIME
SPEAKER
AFFILIATION
8:30 - 09:00
Jason Roy
Rutgers
A Bayesian Semiparametric Model for Sequential Treatment Decisions in Continuous Time
09:00 - 09:30
Jonathan French
Metrum
Using DAGs to Inform Pharmacometric Modeling
09:30 - 09:50
Cedric Taverne
GSK
Vaccine immunogenicity demonstration on cellular responses using Bayesian zero-inflated beta regression to improve preclinical decision-making on small sample sizes
09:50 - 10:10
Coffee Break
10:10 - 10:40
Tianhui Zhang
AstraZeneca
Bayesian statistics for continuous assay qualification
10:40 - 11:00
Ji Young Kim
Merck
A Bayesian Approach For Evaluating Equivalence over Multiple Groups, and Comparison With Frequentist TOST
11:00 - 11:20
Kyle Wathen
Cytel
Platform Trials, Can they Benefit Animal Studies?
11:20 - 11:40
José G. Ramírez & Fang Chen
Kite, a Gilead Company & SAS Institute
Lower Tolerance Bound for the Minimum of Viabilities
11:40 - 12:10
Paul Faya & Cathy (Chang) Xie
Lilly & Baylor U.
Adaptive Borrowing based on Prior Effective Sample Size